Table 1. Baseline demographic, clinicopathological characteristics and phenotypical features of the whole ICC series (n=412).
| Variables | Training cohort (n=214) | Validation cohort (n=108) | External validation cohort (n=90) |
|---|---|---|---|
| Clinical features | |||
| Gender (male vs. female) | 123/91 | 71/37 | 53/37 |
| Age, median (range), years | 58 [31–81] | 58 [27–79] | 64 [36–93] |
| HBV infection (negative vs. positive) | 85/129 | 38/70 | 20/70 |
| AFP (ng/mL) (<20 vs. ≥20) | 193/21 | 93/15 | 80/10 |
| CA-199 (U/mL) (<37 vs. ≥37) | 103/111 | 60/48 | 47/43 |
| Lymphonodus metastasis (absent vs. present) | 177/37 | 89/19 | 62/28 |
| TNM stage (I vs. II+III) | 164/50 | 83/25 | 67/23 |
| Child-Pugh stage (A vs. B) | 205/9 | 106/2 | 65/25 |
| General macroscopic | |||
| Tumor number (single vs. multiple) | 168/46 | 76/32 | 69/21 |
| Tumor size (≤5 vs. >5) | 91/123 | 54/54 | 33/57 |
| Macrovascular invasion (absent vs. present) | 181/33 | 95/13 | 75/15 |
| General microscopic | |||
| Liver cirrhosis (absent vs. present) | 154/60 | 82/26 | 62/28 |
| Microvascular invasion (absent vs. present) | 181/33 | 95/13 | 75/15 |
| Tumor encapsulation (complete vs. none) | 21/193 | 18/90 | 19/71 |
| Tumor differentiation (I+II vs. III+IV) | 133/81 | 64/44 | 63/27 |
| Follow-up | |||
| Survival (no vs. yes) | 61/153 | 40/68 | 67/23 |
| Recurrence (no vs. yes) | 84/130 | 38/70 | 14/76 |
| Recurrence (≤2 vs. >2 years) | 101/29 | 63/7 | 38/38 |
ICC, intrahepatic cholangiocarcinoma; CA-199, carbohydrate antigen 199; TNM, tumor-nodes-metastases.